Healio April 10, 2018
Lee TT, Kesselheim AS

In a new commentary published in Annals of Internal Medicine, experts suggest that the FDA’s Digital Health Software Precertification Program may lead to less rigorous FDA oversight and studies of safety and effectiveness of marketed digital health apps, with uncertain patient outcomes.

“The [FDA’s] Digital Health Software Precertification (Pre-Cert) Program is designed to expedite regulatory review for companies that demonstrate quality and organizational excellence in software development,” Theodore T. Lee, BA, from Yale University, and Aaron S. Kesselheim, MD, JD, MPH, from Brigham and Women’s Hospital and Harvard Medical School, wrote. “Although Pre-Cert is intended to promote the worthy goals of access and innovation in digital health, many questions have been raised.”

SEE ALSO
...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Apps, Digital Health, FDA, Govt Agencies, mHealth, Technology
Artificial heart saves 4th patient
PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain
FDA struggles to retain inspectors: GAO
How Do You Construct a Safe, Effective Algorithm?
FDA Aligns with Pharmacists in Ensuring Integrity of Drug Supply Chain | ASPL 2024

Share This Article